• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

AstraZeneca Appoints New Head of Oncology


January 12, 2017

Following the departure in December, Mondher Mahjoubi, who left to become CEO of Innate Pharma (Marseille, France), AstraZeneca (AZ) has announced it has appointed Dr. Jamie Freedman as its new head of oncology.   Dr. Freedman joins from AZ subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca's biologics portfolio.   Prior to this, Dr Freedman held R&D leadership roles at GlaxoSmithKline and OPKO Health, and was formerly president and CEO of biotech Locus Pharmaceuticals.

Related Videos